Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwama N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved survival outcomes in patients with MET-dysregulated advanced NSCLC treated with MET inhibitors: results of a multinational retrospective chart review. Clin Lung Cancer. 2023 Nov;24(7):641-650.e. doi: 10.1016/j.cllc.2023.08.011
Ayad M, Karanth S, Narat M, Luther K, Patel B. Outcomes of creating an automated repeat lactate rule in sepsis patients with lactate levels ≥2. Poster presented at the 2019 Institute for Healthcare Improvement (IHI) Scientific Symposium; December 2019. Orlando, FL. [abstract] BMJ Open Qual. 2019; 8(Suppl 2):A39. doi: 10.1136/bmjoq-2019-ihi.23
Shi K, Zhao Y, Miao L, Satterlee A, Haynes M, Luo C, Musetti S, Huang L. Dual functional LipoMET mediates envelope-type nanoparticles to combinational oncogene silencing and tumor growth inhibition. Mol Ther. 2017 Jul 5;25(7):1567-79. doi: 10.1016/j.ymthe.2017.02.008
Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.